1、Breakthroughs that change patients lives July 30,2024Second Quarter 2024 Earnings TeleconferenceIntroductionFrancesca DeMartinoChief Investor Relations Officer,Senior Vice President3Second Quarter 2024 EarningsForward-Looking Statements and Non-GAAP Financial Informationl Our discussions during this

2、 conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.We include forward-looking statements about,among other topics,our anticipated oper

3、ating and financial performance,including financial guidance and projections;changes to Pfizers commercial organization;reorganizations;business plans,strategy,goals and prospects;our Environmental,Social and Governance(ESG)priorities,strategy and goals;expectations for our product pipeline,in-line

4、products and product candidates,including anticipated regulatory submissions,data read-outs,study starts,approvals,launches,clinical trial results and other developing data,revenue contribution and projections,potential pricing and reimbursement,potential market dynamics,including demand,market size

5、 and utilization rates and growth,performance,timing of exclusivity and potential benefits;strategic reviews;capital allocation objectives;an enterprise-wide cost realignment program(including anticipated costs,savings and potential benefits);a manufacturing optimization program to reduce our cost o

6、f goods sold(including anticipated costs,savings and potential benefits);dividends and share repurchases;plans for and prospects of our acquisitions,dispositions and other business development activities,including our December 2023 acquisition of Seagen,and our ability to successfully capitalize on